![]()
|
|
||||||||
J. Biol. Chem., Vol. 283, Issue 35, 23636-23644, August 29, 2008
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||



1
2
From the
Institute of Biochemistry and Molecular Medicine, University of Bern, Bühlstrasse 28, 3012 Bern, Switzerland and
The Wellcome Trust Biocentre, Division of Biological Chemistry and Drug Discovery, University of Dundee, Dundee DD1 5EH, Scotland, United Kingdom
Phosphatidylethanolamine is a major phospholipid class of all eukaryotic cells. It can be synthesized via the CDP-ethanolamine branch of the Kennedy pathway, by decarboxylation of phosphatidylserine, or by base exchange with phosphatidylserine. The contributions of these pathways to total phosphatidylethanolamine synthesis have remained unclear. Although Trypanosoma brucei, the causative agent of human and animal trypanosomiasis, has served as a model organism to elucidate the entire reaction sequence for glycosylphosphatidylinositol biosynthesis, the pathways for the synthesis of the major phospholipid classes have received little attention. We now show that disruption of the CDP-ethanolamine branch of the Kennedy pathway using RNA interference results in dramatic changes in phosphatidylethanolamine, phosphatidylserine, and phosphatidylcholine. By targeting individual enzymes of the pathway, we demonstrate that de novo phosphatidylethanolamine synthesis in T. brucei procyclic forms is strictly dependent on the CDP-ethanolamine route. Interestingly, the last step in the Kennedy pathway can be mediated by two separate activities leading to two distinct pools of phosphatidylethanolamine, consisting of predominantly alk-1-enyl-acyl- or diacyl-type molecular species. In addition, we show that phosphatidylserine in T. brucei procyclic forms is synthesized exclusively by base exchange with phosphatidylethanolamine.
Received for publication, May 12, 2008 , and in revised form, June 20, 2008.
* The work was supported in part by Swiss National Science Foundation Grant 3100A0-116627 (to P. B.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 Supported by Wellcome Trust Programme Grant 071463.
2 To whom correspondence should be addressed: Institute of Biochemistry and Molecular Medicine, Universität Bern, Bühlstrasse 28, 3012 Bern, Switzerland. Fax: 41-31-631-3737; E-mail: peter.buetikofer{at}mci.unibe.ch.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |